Process key to pain management

Article

An optometrist's understanding of ocular pain management must always be evolving as you become more immersed in primary care, but, according to recent literature, most doctors under evaluate a patient's pain and discomfort and often don't prescribe enough medication.

Bruce E. Onofrey, OD, RPh, FAAO, clinical professor at the University Eye Institute of the University of Houston, provided an update on pain management, focusing on how optometrists can better understand and treat their patients' pain, and reviewed analgesics for ocular pain at the 3rd annual American Optometric Society meeting here in February.

"You should always be aware of the patient's pain," Dr. Onofrey said.

Acetaminophen

The mechanism of acetaminophen is not fully understood, but Dr. Onofrey noted it does lower fever without producing an anti-inflammatory effect or inhibiting platelets. It's often the drug of choice for children, pregnant women, and nursing mothers.

However, acetaminophen has also been associated with liver failure, he said. Those at greatest risk are children and adults who drink alcohol more than three times a day.

Opiates

Endogenous endorphins stimulate the morphine opioid receptors in the brain and spinal column. Opiates bind to these receptors and block the central pain receptors to produce an analgesic or sedative effect, Dr. Onofrey said. Schedule II opiates have high risk of abuse, while schedule V drugs have the lowest risk of abuse.

Common side effects of opiates include itching, nausea, urinary tract problems, drowsiness, and decreased respiration, according to Dr. Onofrey. "These are normal physiological responses," he said, and not the signs of an allergic reaction. Because opiates can decrease the respiratory rate, never prescribe them in a patient with chronic occlusive pulmonary disease or sleep apnea, he said.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.